Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: A novel risk stratification model

BJU International

Volumn 112, Issue 4, 2013, Pages

  Spiess, Philippe E ^a   Levy, David A ^b   Mouraviev, Vladimir ^c   Pisters, Louis L ^d   Jones, J Stephen ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biochemical failure; nadir PSA; prostate cancer; risk groups; salvage cryotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL PROGRESSION FREE SURVIVAL; CANCER PROGNOSIS; CRYOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; SALVAGE PROSTATE WHOLE GLAND CRYOTHERAPY; SALVAGE THERAPY;

BIOCHEMICAL FAILURE; NADIR PSA; PROSTATE CANCER; RISK GROUPS; SALVAGE CRYOTHERAPY;

AGED; AGED, 80 AND OVER; CRYOTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 84880826316     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11695.x     Document Type: Article

References (16)

1. Crook JM, Malone S, Perry G, et al. Twenty-four month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer 2009; 115: 673-679
2. Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir levels as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002; 54: 677-685
3. Mouraviev V, Spiess PE, Jones JS,. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 2012; 61: 1204-1211
4. Spiess PE, Katz AE, Chin JL, et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2010; 106: 194-198
5. Pisters LL, Perrotte P, Scott GM, et al. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 1999; 17: 2514-2520
6. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002; 20: 2664-2671
7. Levy DA, Pisters LL, Jones JS,. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int 2010; 106: 986-990
8. Spiess PE, Lee AK, Leibovici D, et al. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006; 107: 275-280
9. Greene GF, Pisters LL, Scott SM, von, Eschenbach AC,. Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol 1998; 160: 86-90
10. Pisters LL, Rewcastle JC, Donnelly BJ, et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180: 559-563
11. Spiess PE, Given RW, Jones JS,. Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line data registry. BJU Int 2011; 110: 217-220
12. Levy DA, Pisters LL, Jones JS,. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009; 182: 931-937
13. Ritch CR, Katz AE,. Prostate cryotherapy: current status. Curr Opin Urol 2009; 19: 177-181
14. Kaplan EL, Ep M,. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
15. Cox D,. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220
16. Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 2011; 29: 595-605